AUTHOR=Tian Liang , Huang Chongfei , Fu Wenkang , Gao Long , Mi Ningning , Bai Mingzhen , Ma Haidong , Zhang Chao , Lu Yawen , Zhao Jinyu , Zhang Xianzhuo , Jiang Ningzu , Lin Yanyan , Yue Ping , Yuan Jinqiu , Meng Wenbo TITLE=Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota JOURNAL=Frontiers in Pharmacology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1217306 DOI=10.3389/fphar.2023.1217306 ISSN=1663-9812 ABSTRACT=

Proton pump inhibitors (PPIs) are the most used acid-inhibitory drugs, with a wide range of applications in the treatment of various digestive diseases. However, recently, there has been a growing number of digestive complications linked to PPIs, and several studies have indicated that the intestinal flora play an important role in these complications. Therefore, developing a greater understanding of the role of the gut microbiota in PPI-related digestive diseases is essential. Here, we summarize the current research on the correlation between PPI-related digestive disorders and intestinal flora and establish the altered strains and possible pathogenic mechanisms of the different diseases. We aimed to provide a theoretical basis and reference for the future treatment and prevention of PPI-related digestive complications based on the regulation of the intestinal microbiota.